China SXT Pharmaceuticals (SXTC) Debt to Equity (2019 - 2025)
Historic Debt to Equity for China SXT Pharmaceuticals (SXTC) over the last 7 years, with Q1 2025 value amounting to $0.01.
- China SXT Pharmaceuticals' Debt to Equity fell 8446.76% to $0.01 in Q1 2025 from the same period last year, while for Mar 2025 it was $0.01, marking a year-over-year decrease of 8446.76%. This contributed to the annual value of $0.01 for FY2025, which is 8446.76% down from last year.
- As of Q1 2025, China SXT Pharmaceuticals' Debt to Equity stood at $0.01, which was down 8446.76% from $0.04 recorded in Q1 2024.
- In the past 5 years, China SXT Pharmaceuticals' Debt to Equity ranged from a high of $0.76 in Q1 2021 and a low of $0.0 during Q1 2022
- For the 5-year period, China SXT Pharmaceuticals' Debt to Equity averaged around $0.17, with its median value being $0.02 (2023).
- In the last 5 years, China SXT Pharmaceuticals' Debt to Equity crashed by 9990.88% in 2022 and then surged by 269708.06% in 2023.
- Quarter analysis of 5 years shows China SXT Pharmaceuticals' Debt to Equity stood at $0.76 in 2021, then crashed by 99.91% to $0.0 in 2022, then surged by 2697.08% to $0.02 in 2023, then surged by 125.54% to $0.04 in 2024, then crashed by 84.47% to $0.01 in 2025.
- Its last three reported values are $0.01 in Q1 2025, $0.04 for Q1 2024, and $0.02 during Q1 2023.